Biocept Azione

Biocept FCF/Debito

Delisted

Il Rapporto Flusso di Cassa Libero / Debiti di Biocept (BIOC) al 6 ago 2026 è -583,44 %. L'anno precedente, Rapporto Flusso di Cassa Libero / Debiti era 84,35 % — una variazione del -791,70% (inferiore).

FCF/Debito

-583,44 %

YoY

-791,70%

Ultimo aggiornamento:

Rapporto Flusso di Cassa Libero / Debiti di Biocept ammonta a 2026 -583,44 % . Rapporto Flusso di Cassa Libero / Debiti di Biocept ammontava a 2025 84,35 % . Diminuisce del -791,70% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Biocept Analisi delle Azioni

Cosa fa Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Biocept azioni

Rapporto Flusso di Cassa Libero / Debiti di Biocept è -583,44 % nel 2026.

Il Rapporto Flusso di Cassa Libero / Debiti di Biocept è passato da 84,35 % a -583,44 %, con una variazione del -791,70 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Biocept di Rapporto Flusso di Cassa Libero / Debiti dal 2006, con valori annuali, grafici e analisi dettagliate.

FCL/Debiti misura la percentuale del debito totale che potrebbe essere ripagata dal flusso di cassa libero. È una misura più rigorosa rispetto a FCO/Debiti in quanto tiene conto delle spese in conto capitale.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Biocept di Rapporto Flusso di Cassa Libero / Debiti con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Leva finanziaria — Biocept

Tutte le Metriche Finanziarie — Biocept